An integrated modelling methodology for estimating the prevalence of centronuclear myopathy.

[en] Centronuclear myopathies (CNM) are a group of rare inherited muscular disorders leading to a significantly reduced quality of life and lifespan. To date, CNM epidemiologic reports provide limited incidence and prevalence data. Here, an integrated model utilizing available literature is proposed to obtain a better estimate of overall CNM patient numbers by age, causative gene, severity and geographic region. This model combines published epidemiology data and extrapolates limited data over CNM subtypes, resulting in patient numbers related to age and disease subtype. Further, the model calculates a CNM incidence twofold the current estimates. The estimated incidence of 17 per million births for severe X-linked myotubular myopathy (XLMTM), the main subtype of CNM, corresponds to an estimated prevalence of 2715 in the US, 1204 in the EU, 688 in Japan and 72 in Australia. In conclusion, the model provides an estimate of the CNM incidence, prevalence and survival, and indicates that the current estimates do not fully capture the true incidence and prevalence. With rapid advances in genetic therapies, robust epidemiologic data are needed to further quantify the reliability of incidence, prevalence and survival rates for the different CNM subtypes.

Disciplines :

Pediatrics
Neurology

Author, co-author :

Vandersmissen, I.

Biancalana, V.

Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques > Neuropédiatrie

Dowling, J. J.

Vander Stichele, G.

Van Rooijen, S.

Thielemans, L.

Language :

English

Title :

An integrated modelling methodology for estimating the prevalence of centronuclear myopathy.

Publication date :

2018

Journal title :

Neuromuscular Disorders

ISSN :

0960-8966

eISSN :

1873-2364

Publisher :

Elsevier, Netherlands

Volume :

Issue :

Pages :

766-777

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 14 February 2019

Statistics

Number of views

46 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Smith, BK, Goddard, M, Childers, MK, Respiratory assessment in centronuclear myopathies. Muscle Nerve 50 (2014), 315–326, 10.1002/mus.24249.
Laporte, J, Hu, LJ, Kretz, C, Mandel, JL, Kioschis, P, Coy, JF, et al. A gene mutated in x-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 13 (1996), 175–182, 10.1038/ng0696-175.
Bitoun, M, Maugenre, S, Jeannet, P-Y, Lacène, E, Ferrer, X, Laforêt, P, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 37 (2005), 1207–1209, 10.1038/ng1657.
Böhm, J, Biancalana, V, Malfatti, E, Dondaine, N, Koch, C, Vasli, N, et al. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. Brain 137 (2014), 3160–3170, 10.1093/brain/awu272.
Nicot, AS, Toussaint, A, Tosch, V, Kretz, C, Wallgren-Pettersson, C, Iwarsson, E, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 39 (2007), 1134–1139, 10.1038/ng2086.
Wilmshurst, JM, Lillis, S, Zhou, H, Pillay, K, Henderson, H, Kress, W, et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 68 (2010), 717–726, 10.1002/ana.22119.
Agrawal, PB, Pierson, CR, Joshi, M, Liu, X, Ravenscroft, G, Moghadaszadeh, B, et al. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. Am J Hum Genet 95 (2014), 218–226, 10.1016/j.ajhg.2014.07.004.
Ceyhan-Birsoy, O, Agrawal, PB, Hidalgo, C, Schmitz-Abe, K, DeChene, ET, Swanson, LC, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology 81 (2013), 1205–1214, 10.1212/WNL.0b013e3182a6ca62.
Herman, GE, Finegold, M, Zhao, W, De Gouyon B, MetzenbergA, Medical complications in long-term survivors with x-linked myotubular myopathy. J Pediatr 134 (1999), 206–214, 10.1016/S0022-3476(99)70417-8.
Bertini, E, Biancalana, V, Bolino, A, Buj Bello, A, Clague, M, Guicheney, P, et al. 118th ENMC international workshop on advances in myotubular myopathy. 26-28 September 2003, Naarden, The Netherlands. (5th workshop of the international consortium on myotubular myopathy) Neuromuscul Disord 14 (2004), 387–396, 10.1016/j.nmd.2004.04.002.
Laporte, J, Blondeau, F, Buj-Bello, A, Mandel, JL, The myotubularin family: from genetic disease to phosphoinositide metabolism. Trends Genet 17 (2001), 221–228, 10.1016/S0168-9525(01)02245-4.
Jungbluth, H, Wallgren-Pettersson, C, Laporte, JF, 198th ENMC international workshop: 7th workshop on centronuclear (myotubular) myopathies. 31st May - 2nd June 2013, Naarden, The Netherlands Neuromuscul Disord 23 (2013), 1033–1043, 10.1016/j.nmd.2013.08.006.
Amburgey, K, McNamara, N, Bennett, LR, McCormick, ME, Acsadi, G, Dowling, JJ, Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol 70 (2011), 662–665, 10.1002/ana.22510.
Verhaart, IEC, Robertson, A, Leary, R, McMacken, G, König, K, Kirschner, J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol 264 (2017), 1465–1473, 10.1007/s00415-017-8549-1.
Verhaart, IEC, Robertson, A, Wilson, IJ, Aartsma-Rus, A, Cameron, S, Jones, CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis, 12, 2017, 124, 10.1186/s13023-017-0671-8.
Institute of mediciene. Rare diseases and orphan products: accelerating research and development. 2010, National Academies Press, Washington, D.C., 10.17226/12953.
McEntagart, M, Parsons, G, Buj-Bello, A, Biancalana, V, Fenton, I, Little, M, et al. Genotype-phenotype correlations in x-linked myotubular myopathy. Neuromuscul Disord 12 (2002), 939–946, 10.1016/S0960-8966(02)00153-0.
Biancalana V. UMD-MTM1 registry n.d.
Biancalana, V, Scheidecker, S, Miguet, M, Laquerrière, A, Romero, NB, Stojkovic, T, et al. Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues. Acta Neuropathol, 2017, 10.1007/s00401-017-1748-0.
Biancalana, V, Beggs, A, Das, S, Jungbluth, H, Kress, W, Nishino, I, et al. Clinical utility gene card for: centronuclear and myotubular myopathies. Eur J Hum Genet, 2012, 20.
Fattori, F, Maggi, L, Bruno, C, Cassandrini, D, Codemo, V, Catteruccia, M, et al. Centronuclear myopathies: genotype–phenotype correlation and frequency of defined genetic forms in an Italian cohort. J Neurol 262 (2015), 1728–1740, 10.1007/s00415-015-7757-9.
Lally, C, Jones, C, Farwell, W, Reyna, SP, Cook, SF, Flanders, WD, Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet J Rare Dis, 12, 2017, 175, 10.1186/s13023-017-0724-z.
Lukacs, Z, Nieves Cobos, P, Wenninger, S, Willis, TA, Guglieri, M, Roberts, M, et al. Prevalence of pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology 87 (2016), 295–298, 10.1212/WNL.0000000000002758.
Bohm, J, Biancalana, V, DeChene, ET, Bitoun, M, Pierson, CR, Schaefer, E, et al. Mutation spectrum in the large gtpase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 33 (2012), 949–959, 10.1002/humu.22067.
Bitoun, M, Bevilacqua, JA, Prudhon, B, Maugenre, S, Taratuto, AL, Monges, S, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 62 (2007), 666–670, 10.1002/ana.21235.
Werlauff, U., Petri, H., Witting, N., Vissing, J, Frequency and phenotype of myotubular myopathy amongst danish patients with congenital myopathy older than 5 years. J Neuromuscul Dis 2 (2015), 167–174.
Echaniz-Laguna, A, Biancalana, V, Böhm, J, Tranchant, C, Mandel, JL, Laporte, J, Adult centronuclear myopathies: a hospital-based study. Rev Neurol 169 (2013), 625–631, 10.1016/j.neurol.2012.12.006.
Savarese, M, Musumeci, O, Giugliano, T, Rubegni, A, Fiorillo, C, Fattori, F, et al. Novel findings associated with MTM1 suggest a higher number of female symptomatic carriers. Neuromuscul Disord 26 (2016), 292–299, 10.1016/j.nmd.2016.02.004.
Nigro, Vincenzo, Savarese, M, Next-generation sequencing approaches for the diagnosis of skeletal muscle disorders. Curr Opin Neurol 29 (2016), 621–627.
Farrar, MA, Vucic, S, Johnston, HM, du Sart, D, Kiernan, MC, Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr 162 (2013), 155–159, 10.1016/j.jpeds.2012.05.067.
Tassie, B, Isaacs, D, Kilham, H, Kerridge, I, Management of children with spinal muscular atrophy type 1 in Australia. J Paediatr Child Health 49 (2013), 815–819, 10.1111/jpc.12291.
Amburgey, K, Tsuchiya, E, de Chastonay, S, Glueck, M, Alverez, R, Nguyen, C-T, et al. A natural history study of X-linked myotubular myopathy. Neurology, 2017, 10.1212/WNL.0000000000004415 10.1212/WNL.0000000000004415.
Annoussamy, M, Lilien, C, Gidaro, T, Gargaun, E, Che, V, Schara, U, et al. Baseline data from patients with myotubular myopathy enrolled in a European prospective and longitudinal natural history study. Neuromuscul Disord 26 (2016), S116–S117, 10.1016/j.nmd.2016.06.114.
Roy, AJ, Van den Bergh, P, Van Damme, P, Doggen, K, Van Casteren, V, Early stages of building a rare disease registry, methods and 2010 data from the belgian neuromuscular disease registry (BNMDR). Acta Neurol Belg 115 (2015), 97–104, 10.1007/s13760-014-0320-0.